

POLICY NAME	Vivjoa (oteseconazole)	POLICY #	3164P
--------------------	------------------------	-----------------	-------

Criteria

Exclusion Criteria – Any of the following prevents coverage

- ☐ 2.1 Vivjoa will not be covered in combination with Brexafemme for the prevention of RVVC

Recurrent Vulvovaginal Candidiasis (RVVC)

- ☐ 1.1 Documented diagnosis of recurrent vulvovaginal candidiasis
- Recurrent defined as ≥ 3 symptomatic episodes of VVC within the previous 12 months
 - Acute episodes must be confirmed VVC as evidenced by positive KOH test
- ☐ 1.2 Age 12 years or older and biologically female
- ☐ 1.3 Patient is post-menopausal or not of reproductive potential due to some other female infertility
- ☐ 1.4 Patient has experienced a recurrence during or following 6 months of oral fluconazole maintenance treatment or has a contraindication to fluconazole